Tubulis acquired by Gilead Sciences
Gilead Sciences acquired Tubulis, a German therapeutics brand, on May 21, 2026.
Transaction summary
- Target
- Tubulis
- Acquirer
- Gilead Sciences
- Seller
- -
- Announced
- -
- Completed
- 2026-05-21
- Geography
- Germany
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-09-11
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
ConfirmedBusiness Wire reported that Gilead Sciences completed its acquisition of Tubulis, strengthening Gilead's oncology portfolio.
Open sourceContinue your research
Related transaction comps
Biotech
Myricx Bio acquired by Novartis
2026-07-06 · Confirmed
View transaction → Antibody-Drug ConjugatesCrossBridge Bio acquired by Eli Lilly
2026-04-14 · Confirmed
View transaction → BiotechAtaiBeckley acquired by Eli Lilly and Company
2026-09-11 · Confirmed
View transaction → BiotechDersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction →